期刊文献+

卡维地洛对麻醉犬血流动力学的影响 被引量:1

Haemodynamic effects of carvedilol on anaesthetized dogs
下载PDF
导出
摘要 目的 观察国产卡维地洛(carvedilol,Car)对动物血流动力学的影响,全面了解该药对心血管系统的作用。方法 杂种家犬麻醉下iv0-1、0-3、1mg·kg-1Car,记录心电、血压、左心室内压、心输出量。结果 Cariv给药可引起麻醉犬平均动脉压、心率、左心室内压及其最大变化速率、左心室做功及总外周血管阻力明显下降,给药后1min即开始起效,给药后1~5min达最大效能,并具有剂量依赖性,1mg·kg-1剂量药效可持续至给药后45min,Car对心输出量及左室舒张末压无明显影响。结论 Car具有较广泛的心血管效应,除通过扩张外周阻力血管降低血压外,尚具有降低心率、抑制心肌收缩性能的作用;试验结果同时提示国产Car兼具α肾上腺素受体和β肾上腺素受体拮抗作用,支持该药为具有S(-)和R(+)构型的外消旋化合物。 AIM To observe the hameodynamic effects of carvedilol(Car) on intact animals and to investigate the affection of this drug on cardiovascular system. METHOD 0 1,0 3,1 0 mg·kg -1 Car was intravenously administered in 8 anaesthetized mongrel dogs, mean artery blood pressure(MAP),left ventricular pressure(LVP),cardiac output(CO) and the ECG was recorded. RESULTS Car can significantly and dose dependently decrease MAP, HR, LVP, LVP±d p /d t max , left ventricular work(LVW) and total peripheral resistance(TPR). For 1 0 mg·kg -1 the effects can be observed at 1 min after Car was given, achieved the maximum at 1~5 min and can last for 45 min. CONCLUSION Car has many effects on the cardiovascular system, besides the fallen MAP induced by the TPR reduction, Car can also decrease the HR and inhibit the contraction ability of the heart. The results also confirmed that Car would be a racemic mixture of the S (-) and R (+) enantiomers with the properties of both β blocking and α blocking agents.
出处 《中国药理学通报》 CAS CSCD 北大核心 1999年第6期554-556,共3页 Chinese Pharmacological Bulletin
关键词 卡维地洛 降压药 高血压 心肌缺血 血流动力学 carvedilol hypertension myocardial ischemia hameodynamics adrenergic antagonist efficacy
  • 相关文献

参考文献2

  • 1Yue T L,Hypertension,1993年,22卷,9期,2208页
  • 2Luigi X C,Clin Pharmacol Ther,1987年,41卷,1期,31页

同被引文献9

  • 1王化洲,金英,张云芳,路德泽.槐胺碱对心肌收缩性和麻醉犬血流动力学的影响[J].中国药理学通报,1995,11(3):224-227. 被引量:8
  • 2张树平,王建波,王巧云,田春林.不同剂量异丙酚对大鼠血流动力学的影响[J].中国药理学通报,1996,12(2):191-192. 被引量:2
  • 3Prichard BNC. Pharmacology and clinical use of moxonidine, a new centrally acting simpatholytic antihyperlensive agen [ J ]. J Human Hyper, 1997,11 (1) :29 -45.
  • 4Prichard B. The use of moxonidine in the treatment of hypertension [J]. J Hyper,1997,15(1):47-56.
  • 5Ernsberger P. Pharmacology of moxonidine: An-imidazoline receptor agonist[ J ]. J Cardiova.scular Pharmacol, 2000,35 ( 1 ) : 27 -41.
  • 6Csete K,Papp G. Effects of moxonidine on coticocerbral blood flow under normal and ischemic conditions in conscious rabbits[ J]. J Cardiovascular Pharmacol, 2000,35(3 ) :417 -21.
  • 7Swedbery K, Bristow M,Cohn JN et al. Effects of sustained-release moxonidine, an imidazoline agonist,on plasma norepinephrine in patients with chronic heart failure[ J ]. J Am Heart Associ, 2002,105 ( 15 ) : 1797 - 803.
  • 8Uonend O, Marsalek P, Russ H et al, Moxonidine treatment of hypertensivepatient with advanced renal failure[ J ]. J Hyper, 2003,21(9) : 1709 - 17.
  • 9Ernsberger P. The I-imidazoline receptor from binding site to therapeutic target in cardiovascular disease [ J ], J Hyper 1997,15(1):9-25.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部